SAN DIEGO, Aug. 4, 2011 /PRNewswire/ — Genelux Corporation, a
privately held, clinical stage biopharmaceutical company developing
diagnostic and therapeutic solutions for cancer and inflammatory
diseases, today announced the appointment of Dr. Catherine J.
Mackey, long-time Pfizer executive, to the Company’s Board of
Directors.
“In a career defined by excellence at every level, Dr. Mackey
brings a unique set of skills and attributes that we believe will
significantly complement and further strengthen the Genelux Board,”
said Aladar A. Szalay, Chairman and Chief Executive Officer. “Her
28 years of industry experience will be a valuable asset,
particularly as we advance the Genelux product pipeline into later
stage trials and prepare the company for the next stage of growth.
Dr. Mackey’s executive experience within a world class
pharmaceutical R&D organization will help us to preserve the
core of scientific innovation that has characterized Genelux
Corporation. I am honored to welcome Catherine Mackey as our third
outside Director”.
Dr. Mackey is the founder and CEO of MindPiece Partners, a
management consulting firm, and the former Sr. Vice President of
Worldwide Research and Development for Pfizer Inc. She has 28 years
of experience in the life science industry.
After receiving her B.S. and Ph.D. degrees in microbiology from
Cornell University, Dr. Mackey spent the first part of her career
in agricultural biotechnology. She worked her way up from bench
scientist to Vice President and head of Research and Development
for DEKALB Genetics Corporation. She was member of DEKALB’s
executive team which sold the company to Monsanto in 1998. Dr.
Mackey joined Pfizer in 1999 to lead Genomic and Proteomic Sciences
for human health in Groton, CT. Soon she was appointed Vice
President and head of Strategic Alliances and in 2001 she was
appointed Sr. Vice President of Pfizer Global R&D and Director
of Pfizer La Jolla – a position she held fo
‘/>”/>
